Does the media refer more to ABUS or UNCY?

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.00 equaled Unicycive Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANRO or UNCY more profitable?

Alto Neuroscience's return on equity of -47.22% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Unicycive Therapeutics N/A -134.69% -84.51%

Is UNCY or SLDB more profitable?

Solid Biosciences' return on equity of -73.42% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Solid Biosciences N/A -73.42% -61.13%

Does the media favor UNCY or SLDB?

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 2 articles in the media. Solid Biosciences' average media sentiment score of 1.08 beat Unicycive Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UNCY or TBPH?

In the previous week, Theravance Biopharma had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer UNCY or PHAT?

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 2 articles in the media. Unicycive Therapeutics' average media sentiment score of 0.00 equaled Phathom Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Unicycive Therapeutics (UNCY) Competitors

$8.02 +0.15 (+1.91%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$8.10 +0.08 (+1.03%)

As of 05:21 AM Eastern

Compare

UNCY vs. ABUS, ANRO, SLDB, TBPH, and PHAT

Should you buy Unicycive Therapeutics stock or one of its competitors? MarketBeat compares Unicycive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Unicycive Therapeutics include Arbutus Biopharma (ABUS), Alto Neuroscience (ANRO), Solid Biosciences (SLDB), Theravance Biopharma (TBPH), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry.

How does Unicycive Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Arbutus Biopharma has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.00 equaled Unicycive Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arbutus Biopharma has a net margin of 83.95% compared to Unicycive Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Unicycive Therapeutics has lower revenue, but higher earnings than Arbutus Biopharma. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.43	-$33.50M	$0.83	5.36
Unicycive Therapeutics	$680K	323.04	-$26.56M	-$2.21	N/A

Arbutus Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 12.36%. Unicycive Therapeutics has a consensus price target of $24.75, suggesting a potential upside of 208.60%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Arbutus Biopharma beats Unicycive Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Unicycive Therapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Unicycive Therapeutics	$680K	323.04	-$26.56M	-$2.21	N/A

Alto Neuroscience currently has a consensus target price of $35.25, suggesting a potential upside of 44.70%. Unicycive Therapeutics has a consensus target price of $24.75, suggesting a potential upside of 208.60%. Given Unicycive Therapeutics' higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Unicycive Therapeutics had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 0 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.00 equaled Unicycive Therapeutics'average media sentiment score.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Unicycive Therapeutics	Neutral

Alto Neuroscience's return on equity of -47.22% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Alto Neuroscience has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

Summary

Unicycive Therapeutics beats Alto Neuroscience on 8 of the 13 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Solid Biosciences?

Unicycive Therapeutics (NASDAQ:UNCY) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Unicycive Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 2 articles in the media. Solid Biosciences' average media sentiment score of 1.08 beat Unicycive Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences' return on equity of -73.42% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Solid Biosciences	N/A	-73.42%	-61.13%

Unicycive Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	323.04	-$26.56M	-$2.21	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Unicycive Therapeutics currently has a consensus price target of $24.75, suggesting a potential upside of 208.60%. Solid Biosciences has a consensus price target of $17.00, suggesting a potential upside of 93.40%. Given Unicycive Therapeutics' higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Solid Biosciences beats Unicycive Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Theravance Biopharma?

Unicycive Therapeutics (NASDAQ:UNCY) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Theravance Biopharma has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	323.04	-$26.56M	-$2.21	N/A
Theravance Biopharma	$107.46M	8.14	$105.89M	$2.20	7.71

In the previous week, Theravance Biopharma had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.05 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Unicycive Therapeutics has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Unicycive Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Theravance Biopharma	104.34%	18.84%	10.94%

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Unicycive Therapeutics presently has a consensus price target of $24.75, suggesting a potential upside of 208.60%. Theravance Biopharma has a consensus price target of $21.40, suggesting a potential upside of 26.10%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Unicycive Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Theravance Biopharma beats Unicycive Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Phathom Pharmaceuticals?

Unicycive Therapeutics (NASDAQ:UNCY) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Unicycive Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 2 articles in the media. Unicycive Therapeutics' average media sentiment score of 0.00 equaled Phathom Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Phathom Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Unicycive Therapeutics has higher earnings, but lower revenue than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	323.04	-$26.56M	-$2.21	N/A
Phathom Pharmaceuticals	$175.11M	4.95	-$221.25M	-$2.12	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%

Unicycive Therapeutics presently has a consensus target price of $24.75, suggesting a potential upside of 208.60%. Phathom Pharmaceuticals has a consensus target price of $24.50, suggesting a potential upside of 125.60%. Given Unicycive Therapeutics' higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$215.58M	$2.96B	$6.44B	$12.38B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-3.63	18.43	24.66	23.99
Price / Sales	323.04	326.44	527.00	106.82
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	5.69	4.11	10.75	6.50
Net Income	-$26.56M	$64.45M	$3.56B	$336.88M
7 Day Performance	13.76%	1.41%	1.00%	-0.14%
1 Month Performance	-0.74%	1.04%	0.43%	0.77%
1 Year Performance	15.56%	23.88%	29.69%	28.49%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	2.5992 of 5 stars	$8.02 +1.9%	$24.75 +208.6%	+12.8%	$215.58M	$680K	N/A	9	News Coverage
ABUS Arbutus Biopharma	1.2335 of 5 stars	$4.49 -0.8%	$5.00 +11.5%	+30.5%	$883.98M	$191.45M	5.39	90	News Coverage
ANRO Alto Neuroscience	1.8788 of 5 stars	$25.09 +9.4%	$35.25 +40.5%	+930.0%	$875.95M	N/A	N/A	N/A	Gap Down
SLDB Solid Biosciences	2.8483 of 5 stars	$8.85 +6.6%	$17.00 +92.2%	+94.9%	$870.69M	N/A	N/A	100	Positive News
TBPH Theravance Biopharma	2.5192 of 5 stars	$16.80 +1.4%	$21.40 +27.4%	+60.5%	$867.84M	$109.78M	7.65	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. ABUS, ANRO, SLDB, TBPH, and PHAT

How does Unicycive Therapeutics compare to Arbutus Biopharma?

Summary

How does Unicycive Therapeutics compare to Alto Neuroscience?

Summary

How does Unicycive Therapeutics compare to Solid Biosciences?

Summary

How does Unicycive Therapeutics compare to Theravance Biopharma?

Summary

How does Unicycive Therapeutics compare to Phathom Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. ABUS, ANRO, SLDB, TBPH, and PHAT

How does Unicycive Therapeutics compare to Arbutus Biopharma?

Which has more volatility & risk, ABUS or UNCY?

Does the media refer more to ABUS or UNCY?

Is ABUS or UNCY more profitable?

Which has better earnings & valuation, ABUS or UNCY?

Do analysts rate ABUS or UNCY?

Do institutionals and insiders hold more shares of ABUS or UNCY?

Summary

How does Unicycive Therapeutics compare to Alto Neuroscience?

Do insiders and institutionals hold more shares of ANRO or UNCY?

Which has better valuation and earnings, ANRO or UNCY?

Do analysts recommend ANRO or UNCY?

Does the media favor ANRO or UNCY?

Is ANRO or UNCY more profitable?

Which has more volatility & risk, ANRO or UNCY?

Summary

How does Unicycive Therapeutics compare to Solid Biosciences?

Which has more risk & volatility, UNCY or SLDB?

Do insiders & institutionals have more ownership in UNCY or SLDB?

Does the media favor UNCY or SLDB?

Is UNCY or SLDB more profitable?

Which has better earnings and valuation, UNCY or SLDB?

Do analysts rate UNCY or SLDB?

Summary

How does Unicycive Therapeutics compare to Theravance Biopharma?

Which has better valuation & earnings, UNCY or TBPH?

Does the media prefer UNCY or TBPH?

Which has more volatility and risk, UNCY or TBPH?

Is UNCY or TBPH more profitable?

Do institutionals & insiders hold more shares of UNCY or TBPH?

Do analysts rate UNCY or TBPH?

Summary

How does Unicycive Therapeutics compare to Phathom Pharmaceuticals?

Which has more risk & volatility, UNCY or PHAT?

Does the media prefer UNCY or PHAT?

Which has higher earnings and valuation, UNCY or PHAT?

Is UNCY or PHAT more profitable?

Do analysts rate UNCY or PHAT?

Do insiders & institutionals hold more shares of UNCY or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools